Biosimilar Diplomacy By Other Means: GPhA CEO Calls Out Amgen Guest
This article was originally published in The Pink Sheet Daily
During speech to the group’s annual meeting, GPhA President Ralph Neas says he is disappointed that Amgen, which is among the firms attending the gathering, is pushing biosimilar substitution restrictions in state legislatures.
You may also be interested in...
Chip Davis still believes in innovation, but now must balance that with affordability in new role leading the generic association.
The generic drug trade association’s cross-cutting priorities are the result of an extensive strategic planning process, CEO Ralph Neas says; the group is planning outreach to Congress and the executive branch to highlight the role generic drugs can play in helping to address the nation’s fiscal problems.
FDA’s Center for Drug Evaluation and Research plans to publish more than 50 new and revised draft guidances this calendar year.